Predictors of XXXX after TACE for @entity157 .

@entity1 @entity82 @entity96 @entity5 @entity648 @entity3929 @entity157 @entity99
AIM: To study predictive factors for @entity99 (TACE) for @entity157 ( @entity157 ). METHODS: Between November 2009 and August 2010, of 254 @entity1 with @entity157 who presented to our multidisciplinary @entity157 clinic for evaluation, 102 (40%) were amenable for TACE. In this prospective study, there were 102 @entity1 with compensated @entity82 with @entity157 and @entity1 -Pugh Class A @entity82 who underwent TACE at the National Liver Institute, Menoufiya University, Egypt. We excluded all @entity1 with prior locoregional therapy, systemic therapy and/or surgical intervention. At baseline and at 1   month postprocedure, laboratory criteria, @entity5 criteria (size, number) and @entity1 -Pugh score were recorded. @entity1 were classified into group 1 (no @entity1 -Pugh point increase after TACE) and group 2 (one or more added @entity1 -Pugh points after TACE, defining @entity99 ). Univariate and multivariate analyses were performed to identify factors predictive of @entity99 . RESULTS: @entity1 were mostly males (82.4%) of mean age 58.4  8.1   years. The only significant changes in laboratory findings at 1   month after TACE were increased international normalised ratio, serum total @entity648 , @entity3929 transaminase and aspartate transaminase and decreased serum albumin and a-fetoprotein (AFP). The statistically significant predictive factors for @entity99 using univariate analysis were found to be baseline lower serum albumin, higher serum a-fetoprotein, more @entity96 (BCLC) stage, larger @entity5 size and a greater number of @entity5 nodules; with logistic regression, multivariate analysis found that at baseline larger @entity5 size (p=0.004 at 95% CI), higher serum AFP (p=0.046 at 95% CI) and lower serum albumin (p=0.033 at 95% CI) predicted decompensation; BCLC stage, number of @entity5 nodules and pre-TACE @entity648 did not predict changes in liver function. CONCLUSIONS: Lower serum albumin and increased @entity5 burden (larger @entity5 size/more nodules and higher a-fetoprotein) at baseline may help predict post-TACE decompensation.
